EMAIL-HF
Implementation of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure Through a New Digital Strategy
Patient / Population Intervention / Exposure Comparison Outcome
In 5,996 patients with heart failure not on an SGLT2 inhibitor, a digital letter inviting specialist review was compared with usual care on initiation of an SGLT2 inhibitor within 6 months.
N
5,996
Design
nationwide registry-based, randomised 1:1 (simple randomisation in monthly batches, May 2023–June 2024), parallel-group; letter does not disclose the trial and controls are unaware of participation; prescribing heart failure specialists blinded to prescription redemption; primary endpoint at 6 months, registry follow-up to 2 years
Endpoint
Proportion of patients initiating an SGLT2 inhibitor (dapagliflozin or empagliflozin) within 6 months of randomisation